Group 1 - The core viewpoint of the article is that Sanofi Bio (300298.SZ) is currently focused on developing its self-researched biosensing technology primarily for monitoring and managing diabetes and related chronic diseases [1] - The company has not yet ventured into the fields of neurointervention or brain-machine interfaces [1] - There are no ongoing preclinical studies specifically targeting neurochemical monitoring [1]

Core Viewpoint - Sanofi Bio (300298.SZ) is currently focused on self-developed biosensing technology primarily for monitoring and managing diabetes and related chronic diseases, with no involvement in neurointervention or brain-computer interface fields, nor has it conducted preclinical research specifically for neurobiochemical monitoring [1] Group 1 - The company is engaged in the development of biosensing technology [1] - The primary application of this technology is in diabetes and related chronic disease management [1] - There is no current involvement in neurointervention or brain-computer interface sectors [1]